CN1268743C - 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 - Google Patents

编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 Download PDF

Info

Publication number
CN1268743C
CN1268743C CNB988049295A CN98804929A CN1268743C CN 1268743 C CN1268743 C CN 1268743C CN B988049295 A CNB988049295 A CN B988049295A CN 98804929 A CN98804929 A CN 98804929A CN 1268743 C CN1268743 C CN 1268743C
Authority
CN
China
Prior art keywords
gly
ala
ser
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988049295A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255163A (zh
Inventor
S·C·埃默里
D·C·布拉凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of CN1255163A publication Critical patent/CN1255163A/zh
Application granted granted Critical
Publication of CN1268743C publication Critical patent/CN1268743C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB988049295A 1997-05-10 1998-05-05 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用 Expired - Fee Related CN1268743C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
GB9709421.3 1997-05-10

Publications (2)

Publication Number Publication Date
CN1255163A CN1255163A (zh) 2000-05-31
CN1268743C true CN1268743C (zh) 2006-08-09

Family

ID=10812048

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988049295A Expired - Fee Related CN1268743C (zh) 1997-05-10 1998-05-05 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用

Country Status (23)

Country Link
US (1) US6339070B1 (enExample)
EP (1) EP0979292B1 (enExample)
JP (1) JP2001526539A (enExample)
KR (1) KR100508136B1 (enExample)
CN (1) CN1268743C (enExample)
AT (1) ATE412755T1 (enExample)
AU (1) AU734915B2 (enExample)
BR (1) BR9808769A (enExample)
CA (1) CA2286875A1 (enExample)
DE (1) DE69840165D1 (enExample)
ES (1) ES2314990T3 (enExample)
GB (2) GB9709421D0 (enExample)
HU (1) HUP0001931A3 (enExample)
IL (1) IL132348A0 (enExample)
MY (1) MY140975A (enExample)
NO (1) NO995475L (enExample)
NZ (1) NZ500014A (enExample)
PL (1) PL337007A1 (enExample)
RU (1) RU2218404C2 (enExample)
SK (1) SK153599A3 (enExample)
TR (1) TR199902731T2 (enExample)
WO (1) WO1998051787A2 (enExample)
ZA (1) ZA983931B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
AU2003239197A1 (en) * 2002-06-07 2003-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Novel stable anti-cd22 antibodies
US20050107320A1 (en) * 2003-01-30 2005-05-19 Matthew During Methods and compositions for use in interventional pharmacogenomics
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
WO2005058236A2 (en) * 2003-12-12 2005-06-30 Genencor International, Inc. Cab molecules
JP4823894B2 (ja) 2004-04-09 2011-11-24 中外製薬株式会社 新規水溶性プロドラッグ
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2633756C (en) * 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
US8263744B2 (en) * 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
WO2010019257A2 (en) 2008-08-13 2010-02-18 The Johns Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN104203982B (zh) * 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105764925A (zh) 2013-10-02 2016-07-13 维文蒂亚生物公司 抗EpCAM抗体和使用方法
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
MX2022011806A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
JP2023520764A (ja) 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法
CN119564851B (zh) * 2024-12-05 2025-08-22 广州骐骥生物科技有限公司 一种冰醋酸透析浓缩液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
US5723287A (en) 1992-09-22 1998-03-03 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
BR9510490B1 (pt) * 1994-12-23 2010-10-05 composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
CA2227040A1 (en) * 1995-08-16 1997-03-06 Zeneca Limited Chemical compounds
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
ES2279539T3 (es) * 1996-05-04 2007-08-16 Astrazeneca Ab Anticuerpo monoclonal anti-cea, conjugados que comprenden dicho anticuerpo, y su uso terapeutico en un sistema adept.
AU747602B2 (en) 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector

Also Published As

Publication number Publication date
WO1998051787A3 (en) 1999-04-01
JP2001526539A (ja) 2001-12-18
TR199902731T2 (xx) 2000-06-21
ATE412755T1 (de) 2008-11-15
HUP0001931A3 (en) 2003-10-28
IL132348A0 (en) 2001-03-19
KR100508136B1 (ko) 2005-08-10
BR9808769A (pt) 2000-08-01
WO1998051787A2 (en) 1998-11-19
ES2314990T3 (es) 2009-03-16
GB2338484B (en) 2001-11-07
CA2286875A1 (en) 1998-11-19
GB9922815D0 (en) 1999-11-24
US6339070B1 (en) 2002-01-15
AU734915B2 (en) 2001-06-28
GB9709421D0 (en) 1997-07-02
PL337007A1 (en) 2000-07-31
EP0979292B1 (en) 2008-10-29
GB2338484A (en) 1999-12-22
NZ500014A (en) 2001-08-31
AU7225498A (en) 1998-12-08
HUP0001931A2 (hu) 2000-09-28
SK153599A3 (en) 2000-06-12
NO995475D0 (no) 1999-11-09
DE69840165D1 (de) 2008-12-11
KR20010012441A (ko) 2001-02-15
ZA983931B (en) 1998-11-10
CN1255163A (zh) 2000-05-31
RU2218404C2 (ru) 2003-12-10
EP0979292A2 (en) 2000-02-16
NO995475L (no) 2000-01-07
MY140975A (en) 2010-02-12

Similar Documents

Publication Publication Date Title
CN1268743C (zh) 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用
CN1224712C (zh) 载体
CN1217956C (zh) 可溶性单链t细胞受体蛋白
CN1241944C (zh) 抗人白介素－5受体α链的抗体
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1163509C (zh) 刺激神经和肾生长的RET配体(RetL)
CN1423660A (zh) 抗体
CN1187374C (zh) 人源化的特异于人4－1bb的抗体和含有它的药物组合物
HK1042503A1 (zh) 表达以及分泌制管张素和endostatin的免疫融合物
CN1604966A (zh) 直接靶定的结合蛋白
CN1095677C (zh) 化合物
CN1756768A (zh) 诱导持久t细胞应答的三聚体多肽构建体
CN1606453A (zh) Cripto阻断抗体及其用途
CA2250579A1 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
CN1636017A (zh) 含有蛋白酶激活序列的气单胞菌溶素原及其在前列腺癌治疗中的使用方法
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1151184A (zh) 对细胞周期非依赖的神经胶质瘤表面抗原特异的人单克隆抗体
CN1649901A (zh) 人癌胚抗原(cea)的特异性抗体片段
WO2008006102A2 (en) Use of retro-aldol reaction to generate reactive vinyl ketone for attachment to anitibody molecules by michael addition reaction for use in immunostaining and immunotargeting
US6838446B1 (en) Vector for expression of GPI-enzyme hybrid
CZ396599A3 (cs) Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo
MXPA99010224A (en) Chemical compounds
CN1913913A (zh) Cab分子
HK1078589A1 (en) Anti-human tenascin monoclonal antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: SIGENTIS CO., LTD.

Effective date: 20070202

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: SIGENTIS CO., LTD.

Free format text: FORMER NAME OR ADDRESS: ZENECA LTD

CP03 Change of name, title or address

Address after: surrey

Patentee after: SYNGENTA LTD.

Address before: England

Patentee before: ZENECA Ltd.

TR01 Transfer of patent right

Effective date of registration: 20070202

Address after: London, England

Patentee after: ASTRAZENECA UK LTD.

Address before: surrey

Patentee before: SYNGENTA LTD.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060809

Termination date: 20100505